1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Yuhan Corporation

Yuhan Corporation

84,700.00
KRW
+700.00
(+0.83%)
2,987.42EPS
22.07P/E
5.17TMarket Cap
Nov 03Next Earn
Yuhan Corporation
KRX:000100
(Korea Stock Exchange)

Recent

price

84,700.00

P/E

ratio

22.07

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
8,120.04
8,658.74
10,040.25
12,204.47
13,308.97
14,870.04
18,283.32
20,367.12
20,935.11
3,713.99
20,376.7
22,325.57
22,522.16
24,786.77
27,585.2
29,282.23
30,613.39
Revenue per Share
1,566.34
1,201.07
1,044.5
1,118.27
1,189.61
1,660.56
2,232.11
1,518.7
792.3
100.37
2,424.79
1,356.92
1,206.67
1,816
943
2,599
3,180.1
Basic EPS, GAAP
1,728.09
731.98
624.45
261.83
731.75
565.96
-145.09
922.28
618.29
48.3
-784.27
226.53
65.32
-799.04
-1,058.08
-515.68
-148.66
Free Cash Flow per Basic Share
123.81
134.3
170.85
170.7
204.43
237.64
284.4
288.97
302.41
57.48
299.15
329.9
330.75
363.59
428.83
501.93
- -
Dividend per Share
14,090.71
14,616.43
15,571.09
16,313.59
17,133.01
18,378.74
21,175.57
22,426.74
23,106.34
23,224.03
25,967.24
27,282.15
28,213.07
29,178.48
28,450.14
31,320.21
32,413.27
Book Value per Share
14,045.64
14,492.91
15,459.05
16,183.01
17,002.44
18,219.12
20,950.81
22,065.72
22,630.5
22,818.43
25,141.15
26,041.18
26,257.55
25,038.83
24,591.23
27,248.52
28,407.31
Tangible Book Value per Share
82
78
77
77
76
76
72
72
73
399
79
76
79
75
75
75
75
Basic Weighted Avg Shares
663,570
679,231
776,458
943,609
1,017,492
1,128,731
1,320,797
1,462,248
1,518,823
1,480,354
1,619,865
1,687,810
1,775,847
1,858,984
2,067,791
2,186,638
2,282,318
Sales/Revenue/Turnover
12.45
7.38
4.46
6.55
7.31
7.6
7.4
6.07
3.3
0.85
5.2
2.88
2.03
3.07
2.65
4.77
5.42
Operating Margin (%)
21,545
17,777
17,432
18,903
26,513
31,056
42,920
52,195
59,000
58,658
59,785
52,671
43,019
44,410
63,041
69,156
77,708
Depreciation Expense
128,002
94,217
80,776
86,461
90,948
126,047
161,249
109,034
57,481
40,006
192,761
102,583
95,144
136,198
70,687
194,079
237,086
Net Income, GAAP
10.5
11.83
24.54
19.29
21.66
25.13
21.3
24.35
34.74
33.33
20.63
21.37
4.57
0.42
10.2
16.78
18.48
Effective Tax Rate (%)
19.29
13.87
10.4
9.16
8.94
11.17
12.21
7.46
3.78
2.7
11.9
6.08
5.36
7.33
3.42
8.88
10.39
Profit Margin (%)
469,965
472,909
500,493
491,239
586,119
602,752
723,907
793,199
761,249
764,724
813,342
792,118
754,743
673,267
741,125
778,077
903,523
Working Capital
- -
- -
- -
18,500
24,100
86,000
140,250
115,339
70,212
49,656
51,029
32,622
3,402
62,390
122,361
72,357
88,917
LT Debt
1,072,720
1,116,723
1,188,217
1,228,246
1,275,865
1,363,940
1,496,552
1,606,325
1,651,736
1,649,991
1,846,502
1,935,889
2,007,806
2,100,656
2,150,670
2,362,284
2,470,993
Total Equity
7.19
3.92
2.24
4
4.41
4.45
4.75
3.87
1.84
0.47
3.58
1.87
1.63
2.57
2.07
3.36
3.74
Return on Invested Capital (%)
12.47
8.58
6.99
7.03
7.05
8.97
10.31
6.52
3.36
2.59
10.63
5.38
4.95
6.56
4.19
8.37
9.83
Return on Capital (%)
12.56
8.62
7.02
7.16
7.27
9.56
11.28
7.05
3.55
2.44
11.07
5.45
4.87
6.75
3.41
8.81
10.45
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
267,318
263,708
260,614
LT Borrowings
71,117
91,117
88,917
LT Finance Leases
1,241
- -
- -
Preferred Equity and Hybrid Capital
1,181
1,181
1,181
Shares Outstanding
74
74
74
Market Capitalization
8,274,414
6,978,776
5,167,828

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,511,630
1,601,282
1,616,324
Cash, Cash Equivalents & STI
378,081
411,035
449,248
Accounts Receivable, Net
694,442
639,913
680,951
Inventories
372,764
437,746
419,982
Total Current Liabilities
733,553
788,489
712,801
Payables & Accruals
- -
- -
- -
ST Debt
267,318
263,708
260,614
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
5.08%
9.84%
Free Cash Flow
-284.93%
-295.99%
-51.45%
Net Income, GAAP
41.53%
23.12%
174.56%
Sales/Revenue/Turnover
6.96%
6.21%
5.75%
Total Cash Common Dividend
7.73%
9.7%
16.6%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
444,593
528,312
598,785
496,101
2,067,791
2025
491,564
578,987
570,014
546,073
2,186,638
2026
526,780
639,452
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
169
428
499
-153.53
943
2025
118
607
342
1,530.61
2,599
2026
362
940
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
427.31
0.09
- -
- -
428.83
2025
- -
- -
- -
- -
501.93
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Yuhan Corporation (000100.KS) manufactures and markets pharmaceuticals, health functional foods, and animal health products in South Korea. The company offers prescription drugs including analgesics, anti-inflammatories, and treatments for gastrointestinal disorders, metabolic diseases, and circulatory conditions; over-the-counter medications such as vitamins, cold remedies, and digestive aids; health functional foods under brands like Lacto; and animal health products including vaccines and feed additives. Yuhan operates primarily in the domestic Korean market with research and development facilities supporting its pharmaceutical pipeline, and it maintains international partnerships for technology transfers. Founded in 1926 and headquartered in Seoul, South Korea, the company recently expanded its animal health division through strategic investments and launched new formulations in its consumer health portfolio amid growing demand for functional foods.